Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
| Main Authors: | , , , , |
|---|---|
| Formato: | Conference item |
| Publicado em: |
BMJ Publishing Group
2018
|